Clinical trial
Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung…
NCT00275132 · University College, London, Other · Completed
Key facts
| NCT number | NCT00275132 |
|---|---|
| Title | Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy |
| Acronym | TOPICAL |
| Lead sponsor | University College, London, Other |
| Collaborators | Cancer Research UK Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride, Matched placebo |
| Enrollment | 670 |
| Start date | Apr 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jan 11, 2006 |
| Last update posted | Dec 3, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: